TITLE

Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes

AUTHOR(S)
Oster, Gerry; Sullivan, Sean D.; Dalal, Mehul R.; Kazemi, Mahmood R.; Rojeski, Maria; Wysham, Carol H.; Sung, Jennifer; Johnstone, Bryan; Cali, Anna M.G.; Wei, L.J.; Traylor, Louise; Anhalt, Henry; Hull, Michelle; Van Vleet, John; Meneghini, Luigi F.
PUB. DATE
November 2016
SOURCE
Postgraduate Medicine;Nov2016, Vol. 128 Issue 8, p731
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: This study aims to compare the effectiveness of insulin glargine 300 U/mL (Gla-300) with its accompanying patient support program with that of other basal insulin and available patient support programs in patients with type 2 diabetes (T2D) in a real-world setting in terms of achieving HEDIS (Healthcare Effectiveness Data and Information Set) individualized glycemic targets without documented symptomatic hypoglycemia. Methods: Achieve Control is a US-based, multicenter, randomized, open-label, active-controlled, parallel group pragmatic Phase IV trial in insulin-naïve patients with T2D uncontrolled on ≥2 oral antidiabetes drugs (OAD) and/or glucagon-like peptide-1 receptor antagonists (GLP-1 RA). Inclusion criteria include a diagnosis of T2D, age ≥18 years, and glycated hemoglobin (HbA1c) between 8.0% and 11.0%. Patients will be assigned to either the Gla-300 or other basal insulin group. The primary end point is the proportion of patients achieving HEDIS HbA1c targets (<8.0% [64 mmol/mol] in patients with comorbidities or aged ≥65 years; <7.0% [58 mmol/mol] in all other patients) without occurrence of symptomatic hypoglycemia (blood glucose ≤70 mg/dL) from baseline to 6 months. Secondary end points include rates of documented symptomatic nocturnal hypoglycemia and severe hypoglycemia; change from baseline in HbA1c, fasting glucose, and body weight; treatment persistence; patient-reported outcomes; and healthcare resource utilization. Planned enrollment is 3270 patients across approximately 400 clinical sites. Conclusion: Pragmatic clinical trials offer the potential to assess comparative effectiveness in broadly based patient populations receiving care (with or without a corresponding educational support program) in real-world clinical settings. The results of Achieve Control should elucidate the benefits of management of T2D with Gla-300 versus other basal insulins in terms of patient outcomes, experiences, and perceptions, and its impact on healthcare resource utilization and cost. Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT02451137.
ACCESSION #
119283065

 

Related Articles

  • Glycaemic control with insulin degludec comparable to that with insulin glargine.  // Diabetes Digest;2011, Vol. 10 Issue 3, p151 

    The article discusses a parallel-group phase II trial on the safety and efficacy of insulin degludec (IDec) as compared with once daily (OD) insulin glargine (IGlar) in insulin-naïve type 2 diabetics.

  • Insulin Glargine: An Updated Review of its Use in the Management of Diabetes Mellitus. Dunn, Christopher J.; Plosker, Greg L.; Keating, Gillian M.; McKeage, Kate; Scott, Lesley J. // Drugs;2003, Vol. 63 Issue 16, p1743 

    Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in...

  • Is There a Need for a Better Basal Insulin? Guthrie, Richard // Clinical Diabetes;Spring2001, Vol. 19 Issue 2, p66 

    Discusses the basal insulin therapy, an integral part of intensive management of type 1 diabetes. Goal of diabetes treatment; Limitations of available basal insulins; Structure and function of insulin analogs; Benefits of insulin glargine in pre-clinical glucose clamp studies and in clinical...

  • Defining the Role of Insulin Detemir in Basal Insulin Therapy. Morales, Javier // Drugs;2007, Vol. 67 Issue 17, p2557 

    Insulin detemir is a novel long-acting insulin analogue with a unique mechanism underlying its prolonged duration of action. Unlike neutral protamine Hagedorn (NH) insulin (insulin suspension isophane) and insulin glargine, which precipitate after administration, insulin detemir remains soluble...

  • Insulin Glargine: A Review of its Therapeutic Use as a Long-Acting Agent for the Management of Type 1 and 2 Diabetes Mellitus. McKeage, K.; Goa, K.L. // Drugs;Aug2001, Vol. 61 Issue 11, p1599 

    Insulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Two modifications of human insulin result in a stable molecule which is soluble in slightly acidic conditions (pH 4.0) and precipitates in the neutral pH of...

  • Patient safety and minimizing risk with insulin administration - role of insulin degludec. Aye, Myint M.; Atkin, Stephen L. // Drug, Healthcare & Patient Safety;2014, Vol. 6, p55 

    Diabetes is a lifelong condition requiring ongoing medical care and patient self-management. Exogenous insulin therapy is essential in type 1 diabetes and becomes a necessity in patients with longstanding type 2 diabetes who fail to achieve optimal control with lifestyle modification, oral...

  • Insulin detemir "good value for money" for type 1 DM in Austria.  // PharmacoEconomics & Outcomes News;12/17/2005, Issue 493, p7 

    The article discusses the results of a study on the advantage of switching type 1 diabetes mellitus patients to insulin detemir basal-bolus therapy. The improvements in quality-adjusted life expectancy were projected for insulin determir versus insulin glargine. The study found that insulin...

  • The Role of Basal Insulin in TYPE 2 DIABETES MANAGEMENT.  // Journal of Family Practice;Oct2005 Supplement, Vol. 54, p2 

    This article cites a study that examines the role of basal insulin in type 2 diabetes management. The clinical benefits of initiating insulin therapy early in the course of type 2 diabetes may delay disease progression and simplify diabetes control. In this study, the researchers reported that...

  • Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus. Keating, Gillian // Drugs;2013, Vol. 73 Issue 6, p575 

    Insulin degludec (Tresiba) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less...

  • Insulin degludec versus insulin glargine.  // Africa Health;May2011, Vol. 33 Issue 4, p66 

    The article reports on the clinical trials which compares the effectiveness and benefits of using insulin degludec against insulin glargine in adult patients with type 2 diabetes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics